Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like B*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	drug_category	drug_category_source	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763400	0.075% KCL IN 5% DEXTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.48	108.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264764500	0.15% KCL IN 5% DEXTROSE AND 0.20% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	3.84	96.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762500	0.15% POTASSIUM CHLORIDE IN 5% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE 0.15 g in 100 mL POTASSIUM CHLORIDE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	10.44	120.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763600	0.22% KCL IN 5% DEXDTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	13.44	112.44	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264230400	0.25% ACETIC ACID IRRIGATION USP, 0.25 g in 100 mL ACETIC ACID, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.44	124.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264230410	0.25% ACETIC ACID IRRIGATION USP, 0.25 g in 100 mL ACETIC ACID, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	8.48	110.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264763800	0.30% KCL IN 5% DEXTROSE AND 0.45% NACL INJECTION USP, 5 g in 100 mL DEXTROSE 0.2 g in 100 mL SODIUM CHLORIDE 0.15 g in 100 mL POT, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	8.40	108.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264959420	0.4% LIDOCAINE HCL AND 5% DEXTROSE INJECTION, 0.8 g in 100 mL LIDOCAINE HYDROCHLORIDE ANHYDROUS 5 g in 100 mL DEXTROSE MO, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	1.92	177.12	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264780020	0.9% SODIUM CHLORIDE INJECTION USP, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	6.00	68.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180032	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 100 mL bag	Brand	FDA	06/01/2023	15.36	174.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180036	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 25 mL bag	Brand	FDA	06/01/2023	24.36	315.52	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264180031	0.9% SODIUM CHLORIDE INJECTION USP, 9 mg in 1 mL SODIUM CHLORIDE, SOLUTION, 50 mL bag	Brand	FDA	06/01/2023	18.48	226.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762320	10% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	7.92	89.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264762200	10% DEXTROSE AND 0.45% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.12	104.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752000	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	6.36	72.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752020	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	8.40	96.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264752010	10% DEXTROSE INJECTION USP, 5 g in 100 mL DEXTROSE, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	9.36	106.08	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264761620	5% DEXTROSE AND 0.20% SODIUM CHLORIDE INJECTION USP, 2.5 g in 100 mL DEXTROSE 0.45 g in 100 mL SODIUM CHLORIDE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	8.64	98.88	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264751020	5% DEXTROSE INJECTION USP, 5 g  in 100 mL DEXTROSE, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	6.96	81.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264751010	5% DEXTROSE INJECTION USP, 5 g  in 100 mL DEXTROSE, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	7.92	89.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264319511	CEFEPIME FOR INJECTION USP AND DEXTROSE INJECTION USP DUPLEX, 1 g  in 50 mL CEFEPIME, POWDER, 50 mL bag	Brand	FDA	06/01/2023	34.56	716.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738960	LACTATED RINGERS IN PLASTIC CONTAINER, 600 mg in 100 mL SODIUM CHLORIDE 310 mg in 100 mL SODIUM LACTATE 30 mg in 1, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	16.60	73.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264757810	MANNITOL INJECTION USP, 20 g in 100 mL MANNITOL, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	93.60	1205.04	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264318511	MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER 1 G, 500 mg  in 50 mL MEROPENEM, POWDER, 50 mL bag	Brand	FDA	06/01/2023	18.24	717.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264446030	NUTRILIPID 20%, 20 g in 100 mL SOYBEAN OIL, SOLUTION, 250 mL bag	Brand	FDA	06/01/2023	23.04	305.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264446010	NUTRILIPID 20%, 20 g in 100 mL SOYBEAN OIL, SOLUTION, 500 mL bag	Brand	FDA	06/01/2023	29.28	387.36	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264220500	PHYSIOLYTE, 0.53 g in 100 mL SODIUM CHLORIDE 0.5 g in 100 mL SODIUM GLUCONATE 0.37 g in, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	9.76	119.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264778000	RINGER'S INJECTION USP, 0.86 g in 100 mL SODIUM CHLORIDE 0.033 g in 100 mL CALCIUM CHLORIDE 0.03 g, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	10.44	120.48	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264220200	RINGER'S IRRIGATION USP, 0.86 g in 100 mL SODIUM CHLORIDE 0.03 g in 100 mL POTASSIUM CHLORIDE 0.033, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	15.04	101.28	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738850	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	8.11	54.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738860	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, 0.9 g in 100 mL SODIUM CHLORIDE, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	5.96	72.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264785000	STERILE WATER FOR INJECTION USP, 1 mL in 1 mL WATER, SOLUTION, 1000 mL bag	Brand	FDA	06/01/2023	3.96	51.84	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738550	STERILE WATER FOR INJECTION USP, 1 mL in 1 mL WATER, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	4.20	48.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738660	STERILE WATER FOR IRRIGATION USP, 100 mL in 100 mL WATER, SOLUTION, 3000 mL bag	Brand	FDA	06/01/2023	6.64	76.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000013	B. Braun Medical Inc.	06/30/2023	00264738650	STERILE WATER FOR IRRIGATION USP, 100 mL in 100 mL WATER, SOLUTION, 2000 mL bag	Brand	FDA	06/01/2023	4.88	59.64	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The Prices noted herein are B. Braun's distributor in-to-stock prices for its authorized distributors, as published by third party database companies, such as Merative, First Databank, Medi-Span and Elsevier. B. Braun's in-to-stock prices may not represent actual transaction prices, and do not include prompt pay or other discounts, rebates, chargebacks, or other reductions in price.  By providing a distributor in-to-stock price, B. Braun does not make any representation or suggestion concerning the amount for which any healthcare provider should be or should seek to be reimbursed or the likelihood of coverage or reimbursement for any referenced product.  These prices should not be considered a reflection of the actual selling prices for products purchased from B. Braun or B. Braun's view of the actual prices at which B. Braun's products may be resold by wholesalers or other customers. **This NDC was not acquired by B. Braun in the past 5 years. ***The Drug Source Type reported in reflects the drug category for this product as reported to CMS in the Medicaid Drug Program System.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035310	ALREX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.2%, 10mL Bottle	Brand	FDA	01/01/2023	31.94	564.24	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035305	ALREX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.2%, 5mL Bottle	Brand	FDA	01/01/2023	15.97	282.13	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208062901	BEPREVE™ (bepotastine besilate), Ophthalmic Solution USP, 1.5%, 10mL Bottle	Brand	FDA	01/01/2023	29.39	519.21	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208062902	BEPREVE™ (bepotastine besilate), Ophthalmic Solution USP, 1.5%, 5mL Bottle	Brand	FDA	01/01/2023	15.37	271.48	09/05/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208044605	BESIVANCE® (besifloxacin), Ophthalmic Suspension Drops, 0.6%, 5mL Bottle	Brand	FDA	01/01/2023	12.10	213.81	01/09/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208044335	LOTEMAX® (loteprednol etabonate), Ointment, 0.5%, 3.5g Tube	Brand	FDA	01/01/2023	19.18	338.82	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050307	LOTEMAX® (loteprednol etabonate), Ophthalmic Gel, 0.5%, 5g Bottle	Brand	FDA	01/01/2023	13.63	240.79	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029910	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 10mL Bottle	Brand	FDA	01/01/2023	33.97	600.17	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029915	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 15mL Bottle	Brand	FDA	01/01/2023	50.51	892.30	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208029905	LOTEMAX® (loteprednol etabonate), Ophthalmic Suspension Drops, 0.5%, 5mL Bottle	Brand	FDA	01/01/2023	16.99	300.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050707	LOTEMAX® SM (loteprednol etabonate), Ophthalmic Gel, 0.38%, 5g Bottle	Brand	FDA	01/01/2023	13.63	240.79	12/23/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208053920	MIOCHOL®-E (acetylcholine chloride),Intraocular Solution Kit, 20mg/2 mL, 1 Vial	Brand	FDA	01/01/2023	6.87	121.36	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208060203	PROLENSA™ (bromfenac), Ophthalmic Solution, 0.07%, 3mL Bottle	Brand	FDA	01/01/2023	19.06	336.67	11/11/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	00187149825	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL Single-Use Drop Dispenser, 60	Brand	FDA	01/01/2023	29.89	528.06	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	00187149605	TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL Single-Use Drop Dispenser, 60	Brand	FDA	01/01/2023	34.08	602.16	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208000202	VITRASE® (hyaluronidase, ovine injection) Solution, Vial (ML), 200 Units/mL, 2 Single Dose Vials	Brand	FDA	01/01/2023	13.68	241.65	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050402	VYZULTA™ (latanoprostene bunod), Ophthalmic Drops, 0.024%, 2.5mL Bottle	Brand	FDA	01/01/2023	13.64	240.89	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208050405	VYZULTA™ (latanoprostene bunod), Ophthalmic Drops, 0.024%, 5mL Bottle	Brand	FDA	01/01/2023	27.27	481.76	10/03/2025	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208053535	ZIRGAN™ (Ganciclovir), Ophthalmic Gel, 0.15%, 5mL Bottle	Brand	FDA	01/01/2023	25.10	443.46	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035810	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3%), Ophthalmic Suspension Drops, 0.3%-0.5%, 10mL Bottle	Brand	FDA	01/01/2023	35.36	624.67	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000096	Bausch + Lomb, Inc.	03/31/2023	24208035805	ZYLET® (loteprednol etabonate 0.5% and tobramycin 0.3%), Ophthalmic Suspension Drops, 0.3%-0.5%, 5mL Bottle	Brand	FDA	01/01/2023	17.68	312.33	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	Brand	FDA	01/01/2023	107.46	1840.62	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	Brand	FDA	01/01/2023	141.66	2426.40	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	Brand	FDA	01/01/2023	322.36	5521.75	06/27/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006410	ATIVAN® Tablets 1mg 1,000s	Brand	FDA	01/01/2023	2843.49	43464.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006301	ATIVAN® Tablets .5mg 100s	Brand	FDA	01/01/2023	217.34	3322.20	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006401	ATIVAN® Tablets 1mg 100s	Brand	FDA	01/01/2023	290.33	4437.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187006501	ATIVAN® Tablets 2mg 100s	Brand	FDA	01/01/2023	462.70	7072.75	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000201	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 100g	Brand	FDA	01/01/2023	42.87	519.28	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000260	BRYHALI™ (halobetasol propionate) Lotion 0.01%, 60g	Brand	FDA	01/01/2023	25.73	311.57	11/02/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	25010030515	DEMSER® (metyrosine), 250mg Capsules, 100ct	Brand	FDA	01/01/2023	2992.25	45136.53	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187065301	DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045%, 1	Brand	FDA	01/01/2023	81.57	1008.54	06/06/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187540004	JUBLIA® (efinaconazole) Topical Solution 10%, 4mL	Brand	FDA	01/01/2023	63.45	745.69	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187540008	JUBLIA® (efinaconazole) Topical Solution 10%, 8mL	Brand	FDA	01/01/2023	126.89	1491.37	04/25/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	Brand	FDA	01/01/2023	97.73	1601.33	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	Brand	FDA	01/01/2023	120.32	1971.48	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	Brand	FDA	01/01/2023	68.46	1121.79	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	66490069110	MYSOLINE 250 mg TABLETS, 100s (primidone)	Brand	FDA	01/01/2023	404.59	6354.44	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	66490069010	MYSOLINE 50 mg TABLETS, 100s (primidone)	Brand	FDA	01/01/2023	117.57	1846.54	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187305050	ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% 50g Pump	Brand	FDA	01/01/2023	57.27	723.24	08/05/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	Brand	FDA	01/01/2023	427.87	4749.80	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014090	VASOTEC® 2.5mg Tablets, 90s	Brand	FDA	01/01/2023	90.00	1541.73	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014210	VASOTEC® 10mg Tablets, 1,000s	Brand	FDA	01/01/2023	1275.72	21851.72	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014230	VASOTEC® 10mg Tablets, 30s	Brand	FDA	01/01/2023	38.27	655.49	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014290	VASOTEC® 10mg Tablets, 90s	Brand	FDA	01/01/2023	114.82	1966.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014030	VASOTEC® 2.5mg Tablets, 30s	Brand	FDA	01/01/2023	30.00	513.93	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014310	VASOTEC® 20mg Tablets, 1,000s	Brand	FDA	01/01/2023	1815.16	31092.04	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014330	VASOTEC® 20mg Tablets, 30s	Brand	FDA	01/01/2023	54.46	932.83	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014390	VASOTEC® 20mg Tablets, 90s	Brand	FDA	01/01/2023	163.37	2798.39	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014130	VASOTEC® 5mg Tablets, 30s	Brand	FDA	01/01/2023	34.80	596.12	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187014190	VASOTEC® 5mg Tablets, 90s	Brand	FDA	01/01/2023	149.39	1788.07	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	Brand	FDA	01/01/2023	106.09	1817.26	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	Brand	FDA	01/01/2023	318.29	5452.11	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	Brand	FDA	01/01/2023	140.05	2398.86	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	03/31/2023	00187045302	ZELAPAR (selegiline HCI) 1.25mg Orally Disintegrating Tablets, 60ct	Brand	FDA	01/01/2023	261.51	5491.72	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000529	Bavarian Nordic Inc	09/30/2023	69401000002	Vivotif, Typhoid Vaccine Live Oral Ty21a, 4 cap	Brand	FDA	07/15/2023	7.44	106.67	07/06/2035	Single Source Drug	229766	None	Bavarian Nordic Inc. acquired Vivotif from Emergent Travel Health (ETH) on May 15th, 2023. Upon review of customer contract incentives and subsequent gross-to-net implications, it was determined the prices and discounts being offered by ETH were not sustainable.  A decision was made to implement a moderate increase of 7.5% to slightly improve the product’s bottom line.  It should be noted that the moderate increase offered an improvement but did not entirely alleviate the deficit.  Bavarian Nordic is committed to providing access to Vivotif across all market segments;  and took action to ensure its continued sustainability and availability	None	None	1	05/15/2023	Emergent Travel Health Inc	None	1	None	99.23	94.50	2023	99.23	None	Product was removed from market in 2020, reintroduced in 2022 by Emergent Travel Health Inc. The product wasthen acquired by Bavarian Nordic in 2023
Rx0000024	Bayer	03/31/2023	50419025091	ADEMPAS 0.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025001	ADEMPAS 0.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025191	ADEMPAS 1 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025101	ADEMPAS 1 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025291	ADEMPAS 1.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025201	ADEMPAS 1.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025391	ADEMPAS 2 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025301	ADEMPAS 2 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025491	ADEMPAS 2.5 MG TABLET 9 count	Brand	FDA	01/01/2023	73.89	1305.09	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419025401	ADEMPAS 2.5 MG TABLET 90 count	Brand	FDA	01/01/2023	738.90	13050.90	02/18/2034	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419048858	Nexavar 200mg 120 Tablets	Brand	FDA	01/01/2023	1255.20	24069.60	09/10/2028	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419017101	Stivarga 40 mg tab 28 count bottle	Brand	FDA	01/01/2023	392.00	7209.44	07/09/2032	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	03/31/2023	50419017103	Stivarga 40 mg tab 3x28 count bottle	Brand	FDA	01/01/2023	1176.00	21628.32	07/09/2032	Single Source Drug	0	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000483	Benuvia Operations, LLC	05/08/2024	78613020130	SYNDROS oral solution 5mg/mL	Brand	FDA	12/18/2023	3112.51	4862.00	06/08/2028	Single Source Drug	None	None	Syndros was acquired by Benuvia Operations, LLC on August 18, 2022. Product required new manufacturing site for API and finished product as well as new sNDA which involved significant costs for a small company. Consequently, R&D costs are the main reason for the price increase. In addition, cost of raw materials, increase in product distribution supply chain fees (new manufacturing site registration and wholesaler, GPO fee increases), general inflation also taken into account.	None	Recent R&D update to the manufacturing process (new DMF) and finished drug product (sNDA) will increase efficiency and manufacturing timeline but has resulted in significant spend for the company as a start up, which only has this one small commercial product.	None	08/18/2022	Benuvia, Inc.	8100000	None	Acquisition included Syndros, manufacturing facility and otehr development assets from Benuvia, Inc in a UCC public sale. The acquisition price is not limited to just Syndros..	1166.66	1166.66	2017	973.00	None	Syndros was launched in 2017 and has gone through several ownership changes. Since it's launch Syndros was not marketed during covid and given the size of Benuvia we have had to incraese the price to pay to move full maufacturing to a new site, supplemental NDA was also submitted this year as well as conducting work on PREA requirement.
Rx0000103	Biocodex USA	09/30/2023	68418793906	Diacomit 250mg Capsule 60ct	Brand	FDA	07/10/2023	138.47	1786.97	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794106	Diacomit 250mg Packet 60ct	Brand	FDA	07/10/2023	138.47	1786.97	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794006	Diacomit 500mg Capsule 60 ct	Brand	FDA	07/10/2023	276.95	3573.95	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	09/30/2023	68418794206	Diacomit 500mg Packet 60ct	Brand	FDA	07/10/2023	276.95	3573.95	None	Single Source Drug	None	1	Since product launch in April 2019, only one price increase (this calendar year) however, due to inflation and operations costs a price increase is needed to offset escalating costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135081102	BRINEURA 30MG/ML INJ,KIT	Brand	FDA	12/01/2023	871.00	31979.00	05/05/2036	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135002001	NAGLAZYME 1MG/ML INJ	Brand	FDA	12/01/2023	62.00	2300.00	11/07/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135075620	PALYNZIQ 10MG/0.5ML INJ,SYR,0.5ML	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135005890	PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135067345	PALYNZIQ 20MG/ML INJ,SYR,1ML	Brand	FDA	12/01/2023	260.00	6150.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135067340	PALYNZIQ 20MG/ML INJ,SYR,1ML - D	Brand	FDA	12/01/2023	26.00	615.00	02/03/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	12/31/2023	68135010001	VIMIZIM 1MG/ML INJ,SOLN,5ML	Brand	FDA	12/01/2023	37.00	1394.00	01/10/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000517	Blue Water Biotech, Inc.	06/30/2023	69681012530	Entadfi Oral Capsule 5-5 MG 30 Capsules per bottle	Brand	FDA	06/30/2023	454.88	550.00	None	Single Source Drug	None	1	None	1	None	1	04/20/2023	Veru Inc.	None	1	$20 million upfront, additional $80 based on predetermined annual sales milestones	95.12	95.12	2022	95.12	None	None
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014130	GILOTRIF 20MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=675	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597013730	GILOTRIF 30MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=673	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597013830	GILOTRIF 40MG TABLET 30	Brand	FDA	01/01/2023	629.14	11114.86	01/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=674	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014360	OFEV 100MG CAPSULE 60	Brand	FDA	01/01/2023	471.22	12251.64	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=676	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2023	00597014360	OFEV 100MG CAPSULE 60	Brand	FDA	07/01/2023	245.03	12496.67	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597014560	OFEV 150MG CAPSULE 60	Brand	FDA	01/01/2023	471.22	12251.64	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=677	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	09/30/2023	00597014560	OFEV 150MG CAPSULE 60	Brand	FDA	07/01/2023	245.03	12496.67	06/07/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
Rx0000038	Boehringer Ingelheim	03/31/2023	00597019705	PRAXBIND 2.5g/50mL Vials 2	Brand	FDA	01/01/2023	267.03	4717.46	07/20/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.hcai.ca.gov/api/report/drug-pricing/attachment?id=678	For Column F, this drug is not listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), and there are no patents listed in the FDA database “Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations”. Patent expiration is provided from the Orange Book listing for an associated drug. Not acquired within the last five years.
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089321	ELIQUIS 2.5 MG Tablet, Bottle of 60 Tablets	Brand	FDA	01/01/2023	31.74	560.75	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089331	ELIQUIS 2.5 MG Tablet, Bottle x 100 Tablets	Brand	FDA	01/01/2023	52.91	934.67	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089470	ELIQUIS 5 MG Tablet Bottle of 74 Tablets	Brand	FDA	01/01/2023	39.15	691.61	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003376474	ELIQUIS 5 MG Tablet, 74 Tablets (1 blister pack of 42 tabs and 1 blister pack of 32 tabs)	Brand	FDA	01/01/2023	39.15	691.61	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089421	ELIQUIS 5 MG Tablet, Bottle of 60 Tablets	Brand	FDA	01/01/2023	31.74	560.75	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	03/31/2023	00003089431	ELIQUIS 5 MG Tablet, Hospital Unit-Dose, Blister Package of 100	Brand	FDA	01/01/2023	52.91	934.67	02/24/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 25% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572071030	Idhifa 100mg 30 Tablets in a bottle	Brand	FDA	07/01/2023	782.20	32070.28	09/16/2034	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572070530	Idhifa 50mg 30 Tablets in a bottle	Brand	FDA	07/01/2023	782.20	32070.28	09/16/2034	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572072012	Inrebic 100mg 120 Capsules in a bottle	Brand	FDA	07/01/2023	607.71	24916.19	09/24/2039	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	21000.00	None	2019	21000.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	00003218713	Orencia 250 MG Intravenous Solution, 1 Vial	Brand	FDA	07/01/2023	32.34	1379.90	12/19/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050100	Pomalyst 1mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050121	Pomalyst 1mg 21 Capsules in abottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050200	Pomalyst 2mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050221	Pomalyst 2mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050300	Pomalyst 3mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050321	Pomalyst 3mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050400	Pomalyst 4mg 100 Capsules in a bottle	Brand	FDA	07/01/2023	2513.40	103049.21	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572050421	Pomalyst 4mg 21 Capsules in a bottle	Brand	FDA	07/01/2023	527.81	21640.34	12/21/2031	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085222	Sprycel 100 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085722	Sprycel 140 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052711	Sprycel 20 mg tablet bottle of 60	Brand	FDA	07/01/2023	232.94	9550.71	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052811	Sprycel 50 mg tablet bottle of 60	Brand	FDA	07/01/2023	465.89	19101.39	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003052411	Sprycel 70 mg tablet bottle of 60	Brand	FDA	07/01/2023	465.89	19101.39	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	00003085522	Sprycel 80 mg tablet bottle of 30	Brand	FDA	07/01/2023	419.84	17213.52	09/28/2026	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	This product was developed by BMS. Columns 14 through 22 are intentionally left blank for this submission, as the drug product was not acquired from another manufacturer within the last 5 years
Rx0000078	Bristol Myers Squibb	09/30/2023	59572089028	Zeposia 0.230.460.92 mg 28 capsules Starter Kit	Brand	FDA	07/01/2023	190.92	7827.56	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7636.64	7636.64	2023	7636.64	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572082030	Zeposia 0.92 mg capsules 30 count bottle	Brand	FDA	07/01/2023	204.55	8386.66	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7068.49	7068.49	2020	7068.49	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	09/30/2023	59572081007	Zeposia 4 0.23 mg tablets 4 0.46mg tablets 7 Day Starter Pack	Brand	FDA	07/01/2023	47.73	1956.90	05/14/2029	Single Source Drug	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	1649.32	1649.32	2020	1649.32	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. This acquisition did not consist of costs for individual assets.